Sweden Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Sweden Pharmaceutical Market is segmented by ATC/Therapeutic Class, Drug Type, and Prescription Type

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
CAGR: 3.9 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Sweden Pharmaceutical market studied was anticipated to show growth with a CAGR of 3.9%. The Swedish pharmaceutical industry is estimated to see an attractive rise over the projected period, attributable to the rising incidence of chronic conditions and the rising demand for drugs. Increased health quality, quick and effective patient relief standards are primary factors for the growth of the market. The discovery of various new diseases and the production of drugs to prevent or treat disease for the same has lead to industry growth in the country. The provision of medical insurance to individuals to cover healthcare bills is another strong influence on this sector. Spending on pharmaceuticals and healthcare in Sweden has seen stable growth in 2018, reflecting the growing demand for new drug manufacturing, infrastructure development, and emerging opportunities for growth and advancement. Both pharmaceutical use and revenues are on the rise and the outlook for the forecast period is significant, guided by the positive trends of the pharmaceutical industry in the country.

Scope of the Report

As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor’s consent. The report also covers the in-depth analysis of qualitative and quantitative data.

By ATC/Therapeutic Class
Digestive orgnas and metabolism
Blood and Blood Forming Organs
Heart and Circulation
Skin Preparation
Urinary and Genital Organs and Sex Hormones
Systemic Hormonal Preparations, Excluding Sex Hormone and Insulin
Antiinfectives For Systemic Use
Tumors and Disorder of Immune System
Musculo-Skeletal System
Nervous System
Antiparasitic Products, Insecticides and Repellents
Respiratory System
Sensory Organs
By Drug Type
By Prescription Type
Prescription Drugs (Rx)
OTC Drugs

Report scope can be customized per your requirements. Click here.

Key Market Trends

Healthcare Expenditure in Sweden

According to the new OECD report of 2019, Sweden has the third-largest healthcare expenditure in the European region, as a percentage of Gross Domestic Product Sweden has the 11.0% in 2017 which is higher relative to the European average of 9.8% and the per capita expenditure in Sweden is EUR 3,872 which is also the third-highest relative to the European average of EUR 2,884. The maximum of public healthcare expenditure is 84 percent which is still greater than the European average which is 79 percent. Healthcare spending is projected to increase in the coming years, and challenges are already being placed on rising demands for long-term treatment. Progress has been made over the last decade in moving initiatives from hospitals to primary and public care, but difficulties persist in improving access to primary care and continuity of treatment, particularly for people with chronic conditions.


Prescription Drugs segment Holds the Largest Share and Expected to do Same in the Forecast Period

The Swedish Prescription Drugs category is expected to reflect the largest proportion in the predicted period. Some of the key market drivers for this sector are advancement in technology, growing geriatric population, rising incidence of chronic diseases such as cardiovascular, cancer, and new product launches. It would also be related to an increasing per-capita healthcare spending in the country and a rise in people's discretionary income, which will drive the market growth of the Prescription drugs segment in the country during the forecast period from 2020-2025. As per the GLOBOCAN 2018, the estimated number of incident cases in 2020 will be 62,603, which will increase up to 77,866 cases by 2040. Further, growing cases of chronic diseases will lead to an increase in the use of prescription drugs that will fuel market growth in the country during the forecast period.

sweden chronic disease.png

Competitive Landscape

The Sweden pharmaceutical market is highly competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions in the country. Some of the Key companies which are currently dominating the market are Abbvie Inc., Merck & Co., Inc., Amgen Inc., Pfizer Inc., and GlaxoSmithKline plc

Table of Contents


    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemiology Data For key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization

      6. 4.1.6 Pipeline Analysis

        1. By Phase

        2. By Sponsor

        3. By Disease

      7. 4.1.7 Statistical Overview

        1. Number of Hospitals

        2. Employment in the Pharmaceutical Sector

        3. R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Geriatric Population

      2. 4.2.2 Rising Incidence of Chronic Disease

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Scenario

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By ATC/Therapeutic Class

      1. 5.1.1 Digestive orgnas and metabolism

      2. 5.1.2 Blood and Blood Forming Organs

      3. 5.1.3 Heart and Circulation

      4. 5.1.4 Skin Preparation

      5. 5.1.5 Urinary and Genital Organs and Sex Hormones

      6. 5.1.6 Systemic Hormonal Preparations, Excluding Sex Hormone and Insulin

      7. 5.1.7 Antiinfectives For Systemic Use

      8. 5.1.8 Tumors and Disorder of Immune System

      9. 5.1.9 Musculo-Skeletal System

      10. 5.1.10 Nervous System

      11. 5.1.11 Antiparasitic Products, Insecticides and Repellents

      12. 5.1.12 Respiratory System

      13. 5.1.13 Sensory Organs

      14. 5.1.14 Various

    2. 5.2 By Drug Type

      1. 5.2.1 Branded

      2. 5.2.2 Generic

    3. 5.3 By Prescription Type

      1. 5.3.1 Prescription Drugs (Rx)

      2. 5.3.2 OTC Drugs


    1. 6.1 Company Profile

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Merck & Co., Inc.

      3. 6.1.3 Amgen Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 GlaxoSmithKline plc

      6. 6.1.6 F. Hoffmann-La Roche AG

      7. 6.1.7 AstraZeneca plc

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 Novartis International AG

      10. 6.1.10 Sanofi S.A.


**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Sweden Pharmaceutical Market market is studied from 2018 - 2026.

The Sweden Pharmaceutical Market is growing at a CAGR of 3.9% over the next 5 years.

Merck & Co., Inc., Amgen Inc., Pfizer Inc., Orifarm Group A/S , Novartis International AG are the major companies operating in Sweden Pharmaceutical Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!